Granisetron: An update on its clinical use in the management of nausea and vomiting

Oncologist

Volumn 9, Issue 6, 2004, Pages 673-686

  Aapro, Matti ^a,b  

^a CLINIQUE DE GENOLIER   (Switzerland)

^b NONE   (Switzerland)

Author keywords

5 HT3 receptor antagonist; Antiemetic; Granisetron; Nausea; Vomiting

Indexed keywords

ANTINEOPLASTIC AGENT; APREPITANT; CARBAMAZEPINE; CARBATRO; CARBUX; CIMETIDINE; CISPLATIN; CLOMIPRAMINE; CYCLOPHOSPHAMIDE; CYTOCHROME P450; DEXAMETHASONE; DIAZEPAM; DOLASETRON MESILATE; DOXORUBICIN; EPIRUBICIN; FLECAINIDE ACETATE; FLUOROURACIL; FLUTAMIDE; GRANISETRON; IMIPRAMINE; LOMUSTINE; METOCLOPRAMIDE; OMEPRAZOLE; ONDANSETRON; PACLITAXEL; PALONOSETRON; PAROXETINE; PROCHLORPERAZINE; QUINIDINE; ROPINIROLE; SELEGILINE; SEROTONIN 3 ANTAGONIST; TROPISETRON; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANOREXIA; ARTICLE; ASTHENIA; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CHILD; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DYSPEPSIA; ECG ABNORMALITY; EXTRAPYRAMIDAL SYMPTOM; HEADACHE; HUMAN; KIDNEY FAILURE; LIVER FAILURE; MOUSE; NONHUMAN; POLYPHARMACY; POSTOPERATIVE NAUSEA AND VOMITING; PRIORITY JOURNAL; PROPHYLAXIS; RADIATION INDUCED EMESIS; SINGLE DRUG DOSE; SOMNOLENCE; VISUAL DISORDER; WHOLE BODY RADIATION;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GRANISETRON; HEART; HUMANS; KIDNEY FAILURE; LIVER FAILURE; NAUSEA; NEOPLASMS; RADIOTHERAPY; VOMITING;

EID: 9144271962     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.9-6-673     Document Type: Article

References (134)

1. Laszlo J. Emesis as limiting toxicity in cancer chemotherapy. In: Laszlo J, ed. Antiemetics and Cancer Chemotherapy. Baltimore: Williams and Wilkins, 1983;1-5.
2. O'Brien BJ, Rusthoven J, Rocchi A et al. Impact of chemotherapy- associated nausea and vomiting on patients' functional status and on costs: survey of five Canadian centres. CMAJ 1993;149:296-302.
3. Sussman N. Reactions of patients to the diagnosis and treatment of cancer. Anticancer Drugs 1995;6(suppl 1):4-8.
4. Osoba D, Zee B, Warr D et al. Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Support Care Cancer 1997;5:307-313.
5. 3 receptor antagonists different? Eur J Cancer 1993;29A:1655.
6. ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm 1999;56:729-764.
7. Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Ann Oncol 1998;9:811-819.
8. Blower P. A pharmacologic profile of oral granisetron (Kytril tablets). Semin Oncol 1995;22(suppl 10):3-5.
9. Van Wijngaarden I, Tulp MT, Soudijn W. The concept of selectivity in 5-HT receptor research. Eur J Pharmacol 1990;138:301-312.
10. Perez EA, Hesketh P, Sandbach J et al. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol 1998;16:754-760.
11. Ferez EA, Lembersky B, Kaywin P et al. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy. Cancer J Sci Am 1998;4:52-58.
12. Aapro M. Methodological issues in antiemetic studies. Invest New Drags 1993;11:243-253.
13. Kamanabrou D. Intravenous granisetron-establishing the optimal dose. The Granisetron Study Group. Eur J Cancer 1992;28A(suppl 1):S6-S11.
14. Navari RM, Kaplan HG, Gralla RJ et al. Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol 1994;12:2204-2210.
15. Navari R, Gandara D, Hesketh P et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group. J Clin Oncol 1995;13:1242-1248.
16. Lehoczky O. About the antiemetic effectivity of granisetron in chemotherapy-induced acute emesis: a comparison of results with intravenous and oral dosing. Neoplasma 1999;46:73-79.
17. Bleiberg HH, Spielmann M, Falkson G et al. Antiemetic treatment with oral granisetron in patients receiving moderately emetogenic chemotherapy: a dose-ranging study. Clin Ther 1995;17:38-51.
18. Burris H, Hesketh P, Cohn J et al. Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy. Cancer J Sci Am 1996;2:85-90.
19. Heron JF, Goedhals L, Jordaan JP et al. Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. The Granisetron Study Group. Ann Oncol 1994;5:579-584.
20. Maisano R, Adamo V, Settineri N et al. Efficacy of two oral dose regimens of granisetron. Anticancer Res 1995;15:2287-2290.
21. Ettinger DS, Eisenberg PD, Fitts D et al. A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy. Cancer 1996;78:144-151.
22. Gralla RJ, Navari RM, Hesketh PJ et al. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol 1998;16:1568-1573.
23. Aapro MS, Thurlimann B, Sessa C et al. A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis. Ann Oncol 2003;14:291-297.
24. Martin JK, Senecal FM, Baker TM et al. Single-dose 1 mg oral granisetron (G) is less costly and as effective as intravenous ondansetron (O) in controlling nausea (N) and vomiting (V) from moderately emetogenic chemotherapy. Proc Am Soc Clin Oncol 1997;16:76a.
25. Markman M, Kennedy A, Webster K et al. Low-dose oral granisetron (1 mg) plus intravenous dexamethasone: efficacy in gynecologic cancer patients receiving carboplatin-based chemotherapy. Gynecol Oncol 1998;71:113-115.
26. Herrington JD, Kwan P, Young RR et al. Randomized, multicenter comparison of oral granisetron and oral ondansetron for emetogenic chemotherapy. Pharmacotherapy 2000;20:1318-1323.
27. Hesketh PJ, Crews JR, Cohen R et al. Antiemetic efficacy of single-dose oral granisetron (1 mg vs 2 mg) with moderately emetogenic chemotherapy. Cancer J 2000;6:157-161.
28. Lehoczky O. Report on the antiemetic effectivity of a single 1 mg oral granisetron in moderately emetogenic chemotherapies of gynecological malignancies. Eur J Gynaecol Oncol 1998;19:449-452.
29. Campos D, Pereira JR, Reinhardt RR et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 2001;19:1759-1767.
30. 1 antagonist aprepitant for the prevention of chemotherapy induced nausea and vomiting. Support Care Cancer 2003;11:390.
31. 1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 2003;97:2290-2300.
32. Koeller JM, Aapro MS, Gralla RJ et al. Antiemetic guidelines: creating a more practical treatment approach. Support Care Cancer 2002;10:519-522.
33. Gralla RJ, Osoba D, Kris MG et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 1999;17:2971-2994.
34. Chang CS, Chen LT, Huang SM et al. Comparison of intravenous granisetron with metoclopramide plus dexamethasone in the prevention of nausea and vomiting associated with emetogenic cytotoxic chemotherapy. Kaohsiung J Med Sci 1997;13:97-102.
35. Park JO, Rha SY, Yoo NC et al. A comparative study of intravenous granisetron versus intravenous and oral ondansetron in the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy. Am J Clin Oncol 1997;20:569-572.
36. Guillem V, Carrato A, Rifa J et al. High efficacy of oral granisetron in the total control of cyclophosphamide-induced prolonged emesis. Proc Am Soc Clin Oncol 1998;17:46a.
37. Raja MA, Ezzat AA, Ibrahim E et al. Prospective comparative study of 5HT-3 antagonists in moderately emetogenic therapy. Proc Am Soc Clin Oncol 1999;18:604a.
38. Yalçin S, Tekuzman G, Baltali E et al. Serotonin receptor antagonists in prophylaxis of acute and delayed emesis induced by moderately emetogenic, single-day chemotherapy: a randomized study. Am J Clin Oncol 1999;22:94-96.
39. Öge A, Alkis N, Öge Ö et al. Comparison of granisetron, ondansetron and tropisetron for control of vomiting and nausea induced by cisplatin. J Chemother 2000;12:105-108.
40. 3 receptor antagonist (RA), demonstrates sustained prevention of nausea and vomiting for 5 days following moderately emetogenic chemotherapy (MEC). Proc Am Soc Clin Oncol 2003;22:760.
41. Rubenstein EB, Gralla RJ, Eisenberg P et al. Palonosetron (PALO) compared with ondansetron (OND) or dolasetron (DOL) for prevention of acute & delayed chemotherapy-induced nausea and vomiting (CINV): combined results of two phase III trials. Proc Am Soc Clin Oncol 2003;22:729.
42. Aapro MS, Selak E, Lichinitser M et al. Palonosetron (PALO) is more effective than ondansetron (OND) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC): results of a phase III trial. Proc Am Soc Clin Oncol 2003;22:726.
43. Zofran® (ondansetron hydrochloride) US Product Information. Research Triangle Park, NC: GlaxoSmithKline.
44. Lindley C, Blower P. Oral serotonin type 3-receptor antagonists for prevention of chemotherapy-induced emesis. Am J Health Syst Pharm 2000;57:1685-1697.
45. Bubalo J, Seelig F, Karbowicz S et al. Randomized open-label trial of dolasetron for the control of nausea and vomiting associated with high-dose chemotherapy with hematopoietic stem cell transplantation. Biol Bone Marrow Transplant 2001;7:439-445.
46. Grote TH, Pineda LF, Figlin RA et al. Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Oral Dolasetron Dose Response Study Group. Cancer J Sci Am 1997;3:45-51.
47. 3-receptor antagonists. Br J Clin Pharmacol 1994;37:525-530.
48. 3-receptors antagonist for the prevention of chemotherapy-induced nausea and vomiting. Ann Oncol 1993;4:481-484.
49. Diemunsch P, Grelot L. Potential of substance P antagonists as antiemetics. Drugs 2000;60:533-546.
50. 3 receptor antagonist, for the prevention of radiation induced emesis during total body irradiation. Bone Marrow Transplant 1991;7:439-441.
51. Prentice HG, Cunningham S, Gandhi L et al. Granisetron in the prevention of irradiation-induced emesis. Bone Marrow Transplant 1995;15:445-448.
52. Belkacemi Y, Ozsahin M, Pene F et al. Total body irradiation prior to bone marrow transplantation: efficacy and safety of granisetron in the prophylaxis and control of radiation-induced emesis. Int J Radiat Oncol Biol Phys 1996;36:77-82.
53. Orchard PJ, Rogosheske J, Burns L et al. A prospective randomized trial of the anti-emetic efficacy of ondansetron and granisetron during bone marrow transplantation. Biol Blood Marrow Transplant 1999;5:386-393.
54. Logue JP, Magee B, Hunter RD et al. The antiemetic effect of granisetron in lower hemibody radiotherapy. Clin Oncol (R Coll Radiol) 1991;3:247-249.
55. Spitzer TR, Friedman CJ, Bushnell W et al. Double-blind, randomized, parallel-group study on the efficacy and safety of oral granisetron and oral ondansetron in the prophylaxis of nausea and vomiting in patients receiving hyperfractionated total body irradiation. Bone Marrow Transplant 2000;26:203-210.
56. Lennan J. Surgical and patient factors involved in postoperative nausea and vomiting. Br J Anaesth 1992;69(suppl 1):24S-32S.
57. Carroll NV, Miederhoff PA, Cox FM et al. Costs incurred by outpatient surgical centers in managing postoperative nausea and vomiting. J Clin Anesth 1994;6:364-369.
58. Mikawa K, Takao Y, Nishina K et al. The antiemetic efficacy of prophylactic granisetron in gynecologic surgery. Anesth Analg 1995;80:970-974.
59. Fujii Y, Saitoh Y, Tanaka H et al. Prophylactic oral antiemetics for preventing postoperative nausea and vomiting: granisetron versus domperidone. Anesth Analg 1998;87:1404-1407.
60. Fujii Y, Tanaka H, Toyooka H. Preoperative oral granisetron prevents postoperative nausea and vomiting. Acta Anaesthesiol Scand 1998;42:653-657.
61. Fujii Y, Tanaka H, Kobayashi N. Granisetron, droperidol, and metoclopramide for preventing postoperative nausea and vomiting after thyroidectomy. Laryngoscope 1999;109:664-667.
62. Fujii Y, Tanaka H, Kawasaki T. Randomized clinical trial of granisetron, droperidol and metoclopramide for the treatment of nausea and vomiting after laparoscopic cholecystectomy. Br J Surg 2000;87:285-288.
63. Fujii Y, Tanaka H, Kawasaki T. Prophylaxis with oral granisetron for the prevention of nausea and vomiting after laparoscopic cholecystectomy: a prospective randomized study. Arch Surg 2001;136:101-104.
64. Fujii Y, Tanaka H, Kawasaki T. Preoperative oral granisetron for the prevention of postoperative nausea and vomiting after breast surgery. Eur J Surg 2001;167:184-187.
65. Mattioli V, Calo A, Pisoni G et al. Oral granisetron as prophylaxis for nausea and vomiting during fluorescein angiography. A multicentre, double-blind, randomised, parallel group, placebo-controlled study. Minerva Anestesiol 1998;64:553-561.
66. Fujii Y, Tanaka H. Preoperative oral granisetron for the prevention of vomiting following paediatric surgery. Paediatr Anaesth 2002;12:267-271.
67. Taylor AM, Rosen M, Diemunsch PA et al. A double-blind, parallel-group, placebo-controlled, dose-ranging, multicenter study of intravenous granisetron in the treatment of postoperative nausea and vomiting in patients undergoing surgery with general anesthesia. J Clin Anesth l997;9:658-663.
68. Yancik R, Ganz PA, Varricchio CG et al. Perspectives on comorbidity and cancer in older patients: approaches to expand the knowledge base. J Clin Oncol 2001;19:1147-1151.
69. Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer 1997;80:1273-1283.
70. Jörgensen T, Johansson S, Kennerfalk A et al. Prescription drug use, diagnoses, and healthcare utilization among the elderly. Ann Pharmacother 2001;35:1004-1009.
71. Duly S. Granisetron (Kytril) clinical safety and tolerance. Semin Oncol 1994;21(suppl 5):10-14.
72. 3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest 2000;18:163-173.
73. Ferez EA, Lembersky B, Kaywin P et al. Intravenous (IV) granisetron vs ondansetron in the prevention of cyclophosphamide-doxorubicin-induced emesis in breast cancer patients: a double-blind crossover study. Proc Am Soc Clin Oncol 1996;15;543a.
74. Audhuy B, Cappelaere P, Martin M et al. A double-blind randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur J Cancer 1996;32A:807-813.
75. Wei JY. Cardiovascular comorbidity in the older cancer patient. Semin Oncol 1995;22(suppl 1):9-10.
76. Gridelli C, Perrone F, Gallo C et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003;95:362-372.
77. Cowan JD, Neidhart J, McClure S et al. Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group Study. J Natl Cancer Inst 1991;83:1077-1084.
78. Faulds D, Balfour JA, Chrisp P et al. Mitoxantrone: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 1991;41:400-449.
79. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995;332:1004-1014.
80. 3 receptor antagonists in antineoplastic therapy-induced emesis. Drug Saf 1998;18:43-56.
81. 3 antagonist. Eur J Cancer 1990;26(suppl 1):S12-S15.
82. Boike SC, Ilson B, Zariffa N et al. Cardiovascular effects of i.v. granisetron at two administration rates and of ondansetron in healthy adults. Am J Health Syst Pharm 1997;54:1172-1176.
83. Carmichael J, Philip PA, Forfar C et al. An open study to assess the safety, tolerance and pharmacokinetics of an intravenous infusion of granisetron given at 3 mg over 30 s in patients receiving chemotherapy for malignant disease. Cancer Chemother Pharmacol 1995;37:134-138.
84. Jantunen IT, Kataja VV, Muhonen TT et al. Effects of granisetron with doxorubicin or epirubicin on ECG intervals. Cancer Chemother Pharmacol 1996;37:502-504.
85. Gray GW, McLellan TM, Ducharme MB. Granisetron shows no pro-arrhythmic effect in normal subjects during or after exercise in a hot environment. Aviat Space Environ Med 1996;67:759-761.
86. Aapro M, Bourke JP. Rapid intravenous administration of granisetron prior to chemotherapy is not arrhythmogenic: results of a pilot study. Eur J Cancer 2003;39:927-931.
87. Carmichael J, Harris AL. The cardiovascular safety of high-dose intravenous granisetron in cancer patients receiving highly emetogenic chemotherapy. Cancer Chemother Pharmacol 2004;53:123-128.
88. Carmichael J, Harris AL. High-dose i.v. granisetron for the prevention of chemotherapy-induced emesis: cardiac safety and tolerability. Anticancer Drugs 2003;14:739-744.
89. Natural Medicines Comprehensive Database. http://www. naturaldatabase.com, accessed 08/03.
90. May FE, Stewart RB, Cluff LE. Drug interactions and multiple drug administration. Clin Pharmacol Ther 1977;22:322-328.
91. Karas S Jr. The potential for drug interactions. Ann Emerg Med 1981;10:627-630.
92. Flockhart DA. Clinically used drugs metabolized by cytochrome P450. http://medicine.iupui.edu/flockhart/, accessed 08/03.
93. Anonymous. Cytochrome P450. 2000. http://www.anaesthetist.com/physiol/ basics/metabol/cyp/cyp.htm, accessed 08/03.
94. Hayes EM. The cytochrome P-450 enzyme system. http://www.edhayes.com/ startp450.html, accessed 08/03.
95. Bloomer JC, Baldwin SJ, Smith GJ et al. Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron. Br J Clin Pharmacol 1994;38:557-566.
96. Dixon CM, Colthup PV, Serabjit-Singh CJ et al. Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos 1995;23:1225-1230.
97. 3-receptor antagonists and the cytochrome P450 system: clinical implications. Cancer J 2002;8:405-414.
98. 3 antagonists. Drug Metab Dispos 1996;24:602-609.
99. 3-receptor antagonist: from pharmacology to clinics. Presented at the MASCC/ISOO Meeting. Berlin, Germany, June 18-21, 2003.
100. Kaiser R, Sezer O, Papies A et al. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 2002;20:2805-2811.
101. Marez D, Legrand M, Sabbagh N et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997;7:193-202.
102. Relling MV, Cherrie J, Schell MJ et al. Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects. Clin Pharmacol Ther 1991;50:308-313.
103. London SJ, Daly AK, Leathart JB et al. Genetic polymorphism of CYP2D6 and lung cancer risk in African-Americans and Caucasians in Los Angeles County. Carcinogenesis 1997;18:1203-1214.
104. Evans DA, Mahgoub A, Sloan TP et al. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 1980;17:102-105.
105. Griese EU, Zanger UM, Brudermanns U et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 1998;8:15-26.
106. Kim MK, Choy JY, Lim H-S et al. Effect of the CYP2D6 genotype on the pharmacokinetics of tropisetron in healthy Korean subjects. Eur J Clin Pharmacol 2003;59:111-116.
107. Cagnoni PJ, Matthes S, Day TC et al. Modification of the pharmacokinetics of high-dose cyclophosphamide and cis-platin by antiemetics, Bone Marrow Transplant 1999;24:1-4.
108. Gilbert CJ, Petros WP, Vredenburgh J et al. Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. Cancer Chemother Pharmacol 1998;42:497-503.
109. Emend® Prescribing Information. Whitehouse Station, NJ: Merck & Co. Inc., 2003
110. Blum RA, Majumdar A, McCrea J et al. Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther 2003;25:1407-1419.
111. Sigsgaard T, Herrstedt J, Christensen P et al. Antiemetic efficacy of a combination therapy with granisetron plus prednisolone plus the dopamine D2 antagonist metopimazine during multiple cycles of moderately emetogenic chemotherapy in patients refractory to previous antiemetic therapy. Support Care Cancer 2000;8:233-237.
112. Aapro MS, Kirchner V, Terrey JP. The incidence of anticipatory nausea and vomiting after repeat cycle chemotherapy: the effect of granisetron. Br J Cancer 1994;69:957-960.
113. Terrey JP, Aapro MS. The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. The Granisetron Study Group. Eur J Clin Res 1996;8:281-288.
114. Carmichael J, Keizer HJ, Cupissol D et al. Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs 1998;9:381-385.
115. de Wit R, de Boer AC, vd Linden GH et al. Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer 2001;85:1099-1101.
116. 3 receptor blockade? Br J Cancer 2002;86:1662-1663.
117. 1 antagonists; a new class of antiemetics. Br J Cancer 2003;88:1823-1827.
118. Krengli M, Lazzari R, Manara M. [The use of granisetron per os in radiotherapy-induced emesis.] Minerva Med 1996;87:605-608. Italian.
119. Palmer R. Efficacy and safety of granisetron (Kytril) in two special patient populations: children and adults with impaired hepatic function. Semin Oncol 1994;21(suppl 5):22-25.
120. Aapro MS; Perugia Consensus; Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). How do we manage patients with refractory or breakthrough emesis? Support Care Cancer 2002;10:106-109.
121. Kytril® granisetron hydrochloride US Prescribing Information (injection and tablets). Nutley, NJ: Hoffmann-La Roche Ltd.
122. Pinkerton CR, Jacobson SJ, Leclerc JM et al. IV granisetron in children receiving highly emetogenic chemotherapy: a double-blind dose-ranging study. Eur J Cancer 1993;29A(suppl 6):S200a.
123. Komada Y, Matsuyama T, Takao A et al. A randomised dose-comparison trial of granisetron in preventing emesis in children with leukaemia receiving emetogenic chemotherapy. Eur J Cancer 1999;35:1095-1101.
124. Tsuchida Y, Hayashi Y, Asami K et al. Effects of granisetron in children undergoing high-dose chemotherapy: a multi-institutional, cross-over study. Int J Oncol 1999;4:673-679.
125. Craft AW, Price L, Eden OB et al. Granisetron as antiemetic therapy in children with cancer. Med Pediatr Oncol 1995;25:28-32.
126. Hählen K, Quintana E, Pinkerton CR et al. A randomized comparison of intravenously administered granisetron versus chlorpromazine plus dexamethasone in the prevention of ifosfamide-induced emesis in children. J Pediatr 1995;126:309-313.
127. Fujii Y, Saitoh Y, Kobayashi N. Prevention of vomiting after tonsillectomy in children: granisetron versus ramosetron. Laryngoscope 2001;11:255-258.
128. Fujii Y, Tanaka H, Ito M. Ramosetron compared with granisetron for the prevention of vomiting following strabismus surgery in children. Br J Ophthalmol 2001;85:670-672.
129. Munro HM, D'Errico CC, Lauder GR et al. Oral granisetron for strabismus surgery in children. Can J Anaesth 1999;46:45-48.
130. Johnson J, Rittenberg C, Börjeson S. A cross-cultural survey of nurses, from Oncology Nursing Society (ONS), European Oncology Nursing Society (EONS) and Multinational Association of Supportive Care in Cancer (MASCC): perception of workload, time constraints and implications for optimising antiemetic treatment. Presented at the ONS Meeting, Denver, Colorado, May 1-4, 2003.
131. Perez EA, Chawla SP, Kaywin PK et al. Efficacy and safety of oral granisetron versus IV ondansetron in prevention of moderately emetogenic chemotherapy-induced nausea and vomiting. Proc Am Soc Clin Oncol 1997;16:43a.
132. 3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy: dose, schedule, and route of administration. Support Care Cancer 1998;6:237-243.
133. 3-receptor antagonists as prophylactic agents for acute chemotherapy-induced emesis. Presented at the MASCC/ISOO Meeting, Berlin, Germany, June 18-21, 2003.
134. 3 antiemetic use in breast cancer patients receiving cyclophosphamide: a multicenter practice evaluation. Support Care Cancer 2003;11:392.